SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

05 Aug 2022 Evaluate
The sales for the June 2022 quarter moved down to Rs. 20583.50 millions as compared to Rs. 22786.70 millions during the year-ago period.The Net Profit of the company slipped to Rs. 1401.00 millions from Rs. 4692.70 millions, a decline of -70.15% on QoQ basis.Operating Profit reported a sharp decline to 2386.20 millions from 5897.80 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 20583.50 22786.70 -9.67 20583.50 22786.70 -9.67 88298.10 72196.80 22.30
Other Income 553.10 392.10 41.06 553.10 392.10 41.06 1998.90 1900.10 5.20
PBIDT 2386.20 5897.80 -59.54 2386.20 5897.80 -59.54 20102.50 21389.40 -6.02
Interest 220.20 90.60 143.05 220.20 90.60 143.05 379.00 429.30 -11.72
PBDT 2166.00 5807.20 -62.70 2166.00 5807.20 -62.70 19723.50 20832.30 -5.32
Depreciation 568.10 517.20 9.84 568.10 517.20 9.84 2189.80 1989.30 10.08
PBT 1597.90 5290.00 -69.79 1597.90 5290.00 -69.79 17533.70 18843.00 -6.95
TAX 196.90 597.30 -67.03 196.90 597.30 -67.03 2121.20 1992.20 6.48
Deferred Tax -78.20 -318.90 -75.48 -78.20 -318.90 -75.48 -917.00 -1326.10 -30.85
PAT 1401.00 4692.70 -70.15 1401.00 4692.70 -70.15 15412.50 16850.80 -8.54
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 11.59 25.88 -55.21 11.59 25.88 -55.21 22.77 29.63 -23.15

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×